Author:
Awada Ahmad,Garcia Agustin A,Chan Stephen,Jerusalem Guy H M,Coleman Robert E,Huizing Manon T,Mehdi Aminder,O'Reilly Sue M,Hamm John T,Barrett-Lee Peter J,Cocquyt Veronique,Sideras Kostandinos,Young David E,Zhao Carol,Chia Yen Lin,Hoch Ute,Hannah Alison L,Perez Edith A
Reference27 articles.
1. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine;Perez;J Clin Oncol,2007
2. Phase II study of the halichondrin b analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine;Cortes;J Clin Oncol,2010
3. First phase I trial of NKTR-102 (PEG irinotecan) reveals early evidence of broad anti-tumor activity in three schedules;Von Hoff;Eur J Cancer,2008
4. A multicenter, phase 1, open-label, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of NKTR-102 in patients with refractory solid tumors;Jameson;Clin Cancer Res,2013
5. PEGylation governs the disposition and metabolism of irinotecan following administration of a novel PEG-irinotecan conjugate;Antonian;Eur J Cancer,2007
Cited by
71 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献